Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Masseter Myofascial Pain Relief Following an Intra-muscular Injection With Botulinum Toxin Type A.

First Posted Date
2020-06-11
Last Posted Date
2020-06-11
Lead Sponsor
Region Örebro County
Target Recruit Count
48
Registration Number
NCT04426123

Effect of Video Game-assisted and BoNT-A Injection Therapy on Spasticity, Activity and Participation in CP Patients

First Posted Date
2020-02-28
Last Posted Date
2020-02-28
Lead Sponsor
Sunnaas Rehabilitation Hospital
Target Recruit Count
25
Registration Number
NCT04290169

A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-02-24
Last Posted Date
2020-07-09
Lead Sponsor
ATGC Co., Ltd.
Target Recruit Count
60
Registration Number
NCT04281095
Locations
🇰🇷

Nowon Eulji Medical Center, Seoul, Korea, Republic of

Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease

First Posted Date
2020-02-20
Last Posted Date
2022-05-17
Lead Sponsor
University of Calgary
Target Recruit Count
40
Registration Number
NCT04277247
Locations
🇨🇦

Movement Disorder Program, Foothills Medical Center, Alberta Health Services, Calgary, Alberta, Canada

Intra-gastric Fundal and Body Injection of Botulinum Toxin A for Weight Loss, a Randomized Controlled Trial

First Posted Date
2020-02-18
Last Posted Date
2020-02-18
Lead Sponsor
Tan Tock Seng Hospital
Target Recruit Count
18
Registration Number
NCT04274608
Locations
🇸🇬

Tan Tock Seng Hospital, Singapore, Singapore

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2019-08-28
Last Posted Date
2023-12-15
Lead Sponsor
St. Olavs Hospital
Target Recruit Count
170
Registration Number
NCT04069897
Locations
🇳🇴

Nevroklinikken Universitetet i Oslo, Oslo Universitetssykehus HF, Oslo, Norway

🇳🇴

Haukeland University Hospital, department of Neurology, Bergen, Norway

🇳🇴

Nordland Hospital, department of Neurology, Bodø, Norway

and more 1 locations

Botulinum Toxin A as a Treatment for Provoked Vestibulodynia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2019-08-15
Last Posted Date
2019-08-15
Lead Sponsor
Karolinska Institutet
Target Recruit Count
90
Registration Number
NCT04057755
Locations
🇸🇪

Danderyd Hospital, Dep. of Obstetrics and Gynecology, Stockholm, Sweden

Muscle Selection for Botulinum Toxin A Injection in Poststroke Elbow Flexor Spasticity

Completed
Conditions
Interventions
First Posted Date
2019-07-30
Last Posted Date
2021-06-23
Lead Sponsor
Izmir Katip Celebi University
Target Recruit Count
55
Registration Number
NCT04036981
Locations
🇹🇷

İlker Şengül, İzmir, In The USA Or Canada, Please Select..., Turkey

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2019-06-14
Last Posted Date
2021-05-19
Lead Sponsor
Croma-Pharma GmbH
Target Recruit Count
355
Registration Number
NCT03985982
Locations
🇺🇸

Tennessee Clinical Research Center, Nashville, Tennessee, United States

Botulinum Toxins Intralesional Injection for Scar Pain

First Posted Date
2019-06-12
Last Posted Date
2019-06-17
Lead Sponsor
Kaohsiung Medical University
Target Recruit Count
20
Registration Number
NCT03982862
Locations
🇨🇳

Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

© Copyright 2024. All Rights Reserved by MedPath